The benefit of cholesterol-lowering drug therapy in patients with existing coronary heart disease (CHD) is well established through clinical trials.
Prevention of recurrent coronary morbidity and mortality in CHD patients is called secondary prevention.
In contrast, primary prevention is delaying or preventing altogether new-onset CHD.
There are three categories of primary prevention : high-risk, moderate-risk, and long-term (life-time).
A recent clinical trial has documented benefit of cholesterol-lowering drugs for prevention of coronary morbidity and mortality and total mortality in hypercholesterolemic, middle-aged men.
This trial lends support for including aggressive cholesterol reduction in high-risk primary prevention.
However, for such therapy to be cost effective at present-day prices of cholesterol-lowering drugs, only those patients in the higher ranges of risk can be selected for treatment.
This leaves a large number of people at moderately high risk for premature CHD because of high cholesterol levels.
These persons deserve increased professional attention to risk reduction.
In general the nondrug approach is indicated.
The latter approach includes eliminating other risk factors, e.g. cigarette smoking and hypertension, and reducing serum cholesterol levels by decreased intakes of saturated fatty acids, cholesterol, and excess total calories. (...)
Mots-clés Pascal : Cardiopathie coronaire, Facteur risque, Prévention, Cholestérolémie, Exercice physique, Chimiothérapie, Coût, Campagne de masse, Homme, Appareil circulatoire pathologie, Education santé, Vaisseau sanguin pathologie, Métabolisme pathologie, Hyperlipémie
Mots-clés Pascal anglais : Coronary heart disease, Risk factor, Prevention, Cholesterolemia, Physical exercise, Chemotherapy, Costs, Mass campaign, Human, Cardiovascular disease, Health education, Vascular disease, Metabolic diseases, Hyperlipemia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0298288
Code Inist : 002B12A03. Création : 15/07/1997.